Literature DB >> 32816199

Positive predictive value for malignancy of uncertain malignant potential (B3) breast lesions diagnosed on vacuum-assisted biopsy (VAB): is surgical excision still recommended?

Marco Lucioni1, Chiara Rossi1, Pascal Lomoro2, Francesco Ballati3, Marianna Fanizza3, Alberta Ferrari4, Carlos A Garcia-Etienne4, Emanuela Boveri1, Giulia Meloni3, Maria Grazia Sommaruga3, Elisa Ferraris5, Angioletta Lasagna5, Elisabetta Bonzano6, Marco Paulli1, Adele Sgarella4, Giuseppe Di Giulio3.   

Abstract

PURPOSE: Breast lesions classified as of "uncertain malignant potential" represent a heterogeneous group of abnormalities with an increased risk of associated malignancy. Clinical management of B3 lesions diagnosed on vacuum-assisted breast biopsy (VABB) is still challenging: surgical excision is no longer the only available treatment and VABB may be sufficient for therapeutic excision. The aim of the present study is to evaluate the positive predictive value (PPV) for malignancy in B3 lesions that underwent surgical excision, identifying possible upgrading predictive factors and characterizing the malignant lesions eventually diagnosed. These results are compared with a subset of patients with B3 lesions who underwent follow-up.
METHODS: A total of 1250 VABBs were performed between January 2006 and December 2017 at our center. In total, 150 B3 cases were diagnosed and 68 of them underwent surgical excision. VABB findings were correlated with excision histology. A PPV for malignancy for each B3 subtype was derived.
RESULTS: The overall PPV rate was 28%, with the highest upgrade rate for atypical ductal hyperplasia (41%), followed by classical lobular neoplasia (29%) and flat epithelial atypia (11%). Only two cases of carcinoma were detected in the follow-up cohort, both associated with atypical ductal hyperplasia at VABB.
CONCLUSION: Open surgery is recommended in case of atypical ductal hyperplasia while, for other B3 lesions, excision with VABB only may be an acceptable alternative if radio-pathological correlation is assessed, if all microcalcifications have been removed by VABB, and if the lesion lacks high-risk cytological features. KEY POINTS: • Surgical treatment is strongly recommended in case of ADH, while the upgrade rate in case of pure FEA, especially following complete microcalcification removal by VABB, may be sufficiently low to advice surveillance as a management strategy. • The use of 11-G- or 8-G-needle VABB, resulting in possible complete diagnostic excision of the lesion, can be an acceptable alternative in case of RS, considering open surgery only for selected high-risk patients. • LN management is more controversial: surgical excision may be recommended following classical LN diagnosis on breast biopsy if an additional B3 lesion is concurrently detected while in the presence of isolated LN with adequate radiological-pathological correlation follow-up alone could be an acceptable option.

Entities:  

Keywords:  Atypical ductal hyperplasia (ADH); Breast cancer; Carcinoma lobular; Image-guided biopsy; Malignant epithelial neoplasms

Mesh:

Year:  2020        PMID: 32816199     DOI: 10.1007/s00330-020-07161-5

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  47 in total

1.  Atypical ductal hyperplasia: Our experience in the management and long term clinical follow-up in 71 patients.

Authors:  Antuono Latronico; Luca Nicosia; Angela Faggian; Francesca Abbate; Silvia Penco; Anna Bozzini; Christine Cannataci; Giovanni Mazzarol; Enrico Cassano
Journal:  Breast       Date:  2017-10-12       Impact factor: 4.380

2.  Outcome of breast lesions diagnosed as lesion of uncertain malignant potential (B3) or suspicious of malignancy (B4) on needle core biopsy, including detailed review of epithelial atypia.

Authors:  Emad A Rakha; Bernard C Ho; Veena Naik; Soumadri Sen; Lisa J Hamilton; Zsolt Hodi; Ian O Ellis; Andrew H S Lee
Journal:  Histopathology       Date:  2011-03-03       Impact factor: 5.087

3.  Stereotactic vacuum-assisted breast biopsy: Comparison between 11- and 8-gauge needles.

Authors:  Irene Ruggirello; Jacopo Nori; Isacco Desideri; Calogero Saieva; Elisabetta Giannotti; Giulia Bicchierai; Diego De Benedetto; Giulio Francolini; Simonetta Bianchi; Vania Vezzosi; Luis Sanchez; Tommaso Susini; Lorenzo Orzalesi; Icro Meattini; Lorenzo Livi; Vittorio Miele
Journal:  Eur J Surg Oncol       Date:  2017-10-06       Impact factor: 4.424

4.  Sonographically guided 11-G directional vacuum-assisted breast biopsy as an alternative to surgical excision: utility and cost study in probably benign lesions.

Authors:  P Alonso-Bartolomé; A Vega-Bolívar; M Torres-Tabanera; E Ortega; M Acebal-Blanco; F Garijo-Ayensa; I Rodrigo; P Muñoz-Cacho
Journal:  Acta Radiol       Date:  2004-07       Impact factor: 1.990

Review 5.  European guidelines for quality assurance in breast cancer screening and diagnosis. Fourth edition--summary document.

Authors:  N Perry; M Broeders; C de Wolf; S Törnberg; R Holland; L von Karsa
Journal:  Ann Oncol       Date:  2007-11-17       Impact factor: 32.976

6.  Flat epithelial atypia on core needle biopsy: which is the right management?

Authors:  Quirino Piubello; Alice Parisi; Albino Eccher; Giovanna Barbazeni; Zeno Franchini; Antonio Iannucci
Journal:  Am J Surg Pathol       Date:  2009-07       Impact factor: 6.394

Review 7.  Outcome of pure mucocele-like lesions diagnosed on breast core biopsy.

Authors:  Emad A Rakha; Abeer M Shaaban; Syeda Asma Haider; Jacquie Jenkins; Sindhu Menon; Christopher Johnson; Rin Yamaguchi; Alison Murphy; Joyce Liston; Eleanor Cornford; Lisa Hamilton; Jonathan James; Ian O Ellis; Andrew H S Lee
Journal:  Histopathology       Date:  2013-02-12       Impact factor: 5.087

8.  Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.

Authors:  Antonio C Wolff; M Elizabeth H Hammond; David G Hicks; Mitch Dowsett; Lisa M McShane; Kimberly H Allison; Donald C Allred; John M S Bartlett; Michael Bilous; Patrick Fitzgibbons; Wedad Hanna; Robert B Jenkins; Pamela B Mangu; Soonmyung Paik; Edith A Perez; Michael F Press; Patricia A Spears; Gail H Vance; Giuseppe Viale; Daniel F Hayes
Journal:  J Clin Oncol       Date:  2013-10-07       Impact factor: 44.544

9.  Vacuum-assisted breast biopsy: a comparison of 11-gauge and 8-gauge needles in benign breast disease.

Authors:  Markus Hahn; Stella Okamgba; Peter Scheler; Klaus Freidel; Gerald Hoffmann; Bernhard Kraemer; Diethelm Wallwiener; Ute Krainick-Strobel
Journal:  World J Surg Oncol       Date:  2008-05-19       Impact factor: 2.754

10.  First International Consensus Conference on lesions of uncertain malignant potential in the breast (B3 lesions).

Authors:  Christoph J Rageth; Elizabeth Am O'Flynn; Christopher Comstock; Claudia Kurtz; Rahel Kubik; Helmut Madjar; Domenico Lepori; Gert Kampmann; Alexander Mundinger; Astrid Baege; Thomas Decker; Stefanie Hosch; Christoph Tausch; Jean-François Delaloye; Elisabeth Morris; Zsuzsanna Varga
Journal:  Breast Cancer Res Treat       Date:  2016-08-13       Impact factor: 4.872

View more
  3 in total

1.  Ultrasound-guided 8-Gauge vacuum-assisted excision for selected B3 breast lesions: a preliminary experience.

Authors:  Giovanna Panzironi; Giuliana Moffa; Francesca Galati; Federica Pediconi
Journal:  Radiol Med       Date:  2021-11-20       Impact factor: 3.469

2.  Surgical management and prognosis of phyllodes tumors of the breast.

Authors:  Yashuang Ji; Yuting Zhong; Yiqiong Zheng; Huayu Hu; Ningning Min; Yufan Wei; Rui Geng; Chenyan Hong; Qingyu Guan; Jie Li; Zhili Wang; Yanjun Zhang; Xiru Li
Journal:  Gland Surg       Date:  2022-06

Review 3.  High-risk lesions of the breast: concurrent diagnostic tools and management recommendations.

Authors:  Francesca Catanzariti; Daly Avendano; Giuseppe Cicero; Margarita Garza-Montemayor; Carmelo Sofia; Emmanuele Venanzi Rullo; Giorgio Ascenti; Katja Pinker-Domenig; Maria Adele Marino
Journal:  Insights Imaging       Date:  2021-05-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.